We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Accept Cookies
Multiple biomarkers are being evaluated to guide the use of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC), including staining of programmed death-ligand 1 (PD-L1) tumor cells. We can accurately quantify PD-L1 status and identify multiple mutations by using a single bronchoscopic specimen.
We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy